Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn’s disease - Summary - MDSpire

Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn’s disease

  • By

  • Matthew Stephens

  • Keith Keane

  • Simon Roizes

  • Manon Defaye

  • Christophe Altier

  • Pierre-Yves von der Weid

  • February 23, 2025

  • 0 min

Share

Objective:

Expand to include significance of TB-independent mechanisms.

Key Findings:
  • Provide context on implications for Crohn's disease treatment.
Interpretation:

Elaborate on differences from traditional therapies.

Limitations:
  • Include potential confounding factors in the mouse model.
Conclusion:

Emphasize need for clinical trials.

Original Source(s)

Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn’s disease

  • by Matthew Stephens, Keith Keane, Simon Roizes, Manon Defaye, Christophe Altier, Pierre-Yves von der Weid

  • February 23, 2025

Related Content

Case Report: Bilateral panuveitis with serous ciliary body and choroidal detachment associated with ulcerative colitis

Integrating Double-Balloon Enteroscopy into the Diagnostic Pathway for Suspected Small Bowel Crohn’s Disease: A Retrospective Study from a Tertiary Care Center

Inter-organ Communication and Pathological Interactions in Chronic Obstructive Pulmonary Disease and Inflammatory Bowel Disease: Insights into the Gut-Lung Axis